SCHEMBL24077086

SCHEMBL24077086

COCCn1nc(NC(=O)OC(C)(C)C)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PTGER1 P34995 2/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ CYP2C9 P11712 1/20 0.37
▸ GSK3B P49841 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ SCN9A Q15858 1/20 0.35
▸ CYP17A1 P05093 2/20 0.35
▸ ATR Q13535 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ BRD9 Q9H8M2 1/20 0.35
▸ GFER P55789 1/20 0.34
▸ PSMB8 P28062 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076851 0.84 MET (0.40) KDM4EPTGER1CYP2C9GSK3BDYRK1A
SCHEMBL24951108 0.80 GSK3B (0.41) PTGER1GSK3BDYRK1APTGDR2MAPK14
SCHEMBL31437460 0.74 GSK3B (0.41) CNR1CNR2GSK3BDYRK1APTGDR2
SCHEMBL26008895 0.72 CNR1 (0.40) KDM4EMEN1KMT2APTGER1CNR1
SCHEMBL13472107 0.71 SMN1; SMN2 (0.54) KDM4EGSK3BDYRK1AMAPK14CYP17A1
SCHEMBL24076248 0.70 KDM4E (0.44) KDM4EMEN1KMT2APOLBALDH1A1
SCHEMBL30863610 0.70 CNR1 (0.38) KDM4EMEN1KMT2ACNR1CNR2
SCHEMBL3650533 0.70 HCAR3 (0.44) KDM4EMEN1KMT2ACNR1CNR2
SCHEMBL25317169 0.69 ATR (0.39) KDM4EKMT2AGSK3BDYRK1ASCN9A
SCHEMBL4897352 0.69 DRD2 (0.47) KDM4EMEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
EP-4157823-A1 COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-04-05 — — EP disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B KDM4E 3777/4885MEN1 1965/4885KMT2A 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback